- Verified Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- Raised against granulocytes of mouse origin
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 1 mM EDTA
- Preparation
- The antibody was purified by chromatography and conjugated with TotalSeq?-B oligomer under optimal conditions.
- Concentration
- 0.5 mg/mL
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C. Do not freeze.
- Application
-
PG -?Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis and the oligomer sequence is confirmed by sequencing. TotalSeq?-B antibodies are compatible with 10x Genomics Single Cell Gene Expression Solutions.
To maximize performance, it is strongly recommended that the reagent be titrated for each application, and that you centrifuge the antibody dilution before adding to the cells at 14,000xg at 2 - 8°C for 10 minutes. Carefully pipette out the liquid avoiding the bottom of the tube and add to the cell suspension. For Proteogenomics analysis, the suggested starting amount of this reagent for titration is ≤ 1.0 ?g per million cells in 100 ?L volume. Refer to the corresponding TotalSeq? protocol for specific staining instructions.
Buyer is solely responsible for determining whether Buyer has all intellectual property rights that are necessary for Buyer's intended uses of the BioLegend TotalSeq? products. For example, for any technology platform Buyer uses with TotalSeq?, it is Buyer's sole responsibility to determine whether it has all necessary third party intellectual property rights to use that platform and TotalSeq? with that platform. - Application Notes
Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C19. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A819. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.420.
The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes in vivo. Additional reported applications (for relevant formats of this clone) include: in vitro complement-mediated cytotoxicity2, in vivo depletion3-5,9, immunoprecipitation1, immunohistochemical staining6 (including paraffin-embedded sections9,16,33-35, acetone-fixed frozen sections11 and zinc-fixed sections15), and Western blotting7. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)20.
Special Note:?For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 108436).
- Additional Product Notes
TotalSeq? reagents are designed to profile protein levels at a single cell level following an optimized protocol similar to the CITE-seq workflow. A compatible single cell device (e.g. 10x Genomics Chromium System and Reagents) and sequencer (e.g. Illumina analyzers) are required. Please contact technical support for more information, or visit biolegend.com/totalseq.
The barcode flanking sequences are GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNNNNN (PCR handle), and NNNNNNNNNGCTTTAAGGCCGGTCCTAGC*A*A (capture sequence). N represents either randomly selected A, C, G, or T, and * indicates a phosphorothioated bond, to prevent nuclease degradation.
View more applications data for this product in our Scientific Poster Library.
- Application References
(PubMed link indicates BioLegend citation) -
- Fleming TJ, et al. 1993. J. Immunol. 151:2399. (IP)
- Brummer E, et al. 1984. J. Leukocyte Biol. 36:505. (CMCD)
- Stoppacciaro A, et al. 1993. J. Exp. Med. 178:151. (Deplete)
- Tumpey TM, et al. 1996. J. Virol. 70:898. (Deplete)
- Czuprynski CJ, et al. 1994. J. Immunol. 152:1836. (Deplete)
- Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
- Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (WB)
- Engwerda CR, et al. 2004. Am. J. Pathol. 165:2123.
- Brown CR, et al. 2004. Infect. Immun. 72:4956. (Deplete, IHC)
- Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC) PubMed
- Li M, et al. 2006. P. Natl. Acad. Sci USA 103:11736. (IHC)
- Dzhagalov I, et al. 2007. Blood 109:1620. (FC) PubMed
- Fazilleau N, et al. 2007. Nature Immunol. 8:753. (FC) PubMed
- Heuser M, et al. 2007. Blood 110:1639. (FC) PubMed
- Wang T, et al. 2007. Infect. Immun. 75:1144. (IHC)
- Bosio CM, et al. 2007. J. Immunol. 178:4538. (IHC)
- Boehme SA, et al. 2009. Int. Immunol. 21:81. (IHC)
- Piao Y, et al. 2012. Neuro Oncol. 14:1379. PubMed
- Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
- Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
- Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
- Fan Q, et al. 2014. Cancer Res. 74:471. PubMed
- Korrer MJ, et al. 2014. PLoS One. 9:91370. PubMed
- Morshed M, et al. 2014. J Immunol. 192:5314. PubMed
- Collins C, et al. 2014. PNAS. 111:9899. PubMed
- Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
- Bianchi G, et al. 2014. Cell Death Dis. 5:1135. PubMed
- Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
- Roderick JE, et al. 2014. PNAS. 111:14436. PubMed
- Distel E, et al. 2014. Circ Res. 115:759. PubMed
- Iwai H, et al. 2015. Tuberculosis. 95:246. PubMed
- Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
- Whiteland J, et al. 1994 J Histochem Cytochem 43:3 (IHC-P)
- Brown C, et al. 2003 J Immunology 171:2 (IHC-P)
- Obregon-Henao A, et al. PLoS One 8:11 (IHC-P)
- RRID
- AB_2832372 (BioLegend Cat. No. 108465)